202 related articles for article (PubMed ID: 1688725)
1. MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.
Oster W; Forsthuber T; Hennekeuser HH; Gamm H; Lindemann A; Schmitz G; Fuhr HG; Hinterberger R; Kreiter H; Thoenes W
Blut; 1990 Jan; 60(1):23-7. PubMed ID: 1688725
[TBL] [Abstract][Full Text] [Related]
2. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I
Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
[TBL] [Abstract][Full Text] [Related]
3. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G
Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460
[TBL] [Abstract][Full Text] [Related]
4. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
6. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
7. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
[TBL] [Abstract][Full Text] [Related]
8. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
9. Updated clinical experience with MACOP-B.
Klimo P; Connors JM
Semin Hematol; 1987 Apr; 24(2 Suppl 1):26-34. PubMed ID: 2438779
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
Wolf M; Matthews JP; Stone J; Cooper IA; Robertson TI; Fox RM
Ann Oncol; 1997; 8 Suppl 1():71-5. PubMed ID: 9187435
[TBL] [Abstract][Full Text] [Related]
11. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
Gemmati D; Ongaro A; Tognazzo S; Catozzi L; Federici F; Mauro E; Della Porta M; Campioni D; Bardi A; Gilli G; Pellati A; Caruso A; Scapoli GL; De Mattei M
Haematologica; 2007 Apr; 92(4):478-85. PubMed ID: 17488658
[TBL] [Abstract][Full Text] [Related]
12. MACOP-B chemotherapy for the treatment of high-grade lymphomas in patients with HIV-1 infection.
Taillan B; Garnier G; Ferrari E; Pesce A; Vinti H; Fuzibet JG; Dujardin P
Acta Haematol; 1993; 89(1):10-2. PubMed ID: 7683165
[TBL] [Abstract][Full Text] [Related]
13. MACOP-B treatment for intermediate and high-grade non-Hodgkin's lymphomas at diagnosis and in relapse.
Tarella C; Gallo E; Ferrero D; Badoni R; Carlesso N; Caracciolo D; Pileri A
Haematologica; 1990; 75(2):149-54. PubMed ID: 1694155
[TBL] [Abstract][Full Text] [Related]
14. [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas].
Krieger G; Kreysing E; Kneba M
Onkologie; 2001 Feb; 24 Suppl 1():49-58. PubMed ID: 11441311
[TBL] [Abstract][Full Text] [Related]
15. Minimizing toxicity of MACOP-B.
Connors JM; Klimo P
J Clin Oncol; 1987 Aug; 5(8):1302-3. PubMed ID: 2442319
[No Abstract] [Full Text] [Related]
16. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
[TBL] [Abstract][Full Text] [Related]
17. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
18. VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
Singer JM; Mijovic A; Pettingale KW; Nethersell A; Dobbs HJ; Samaratunga IR; Lakhani A; Mufti GJ
Clin Oncol (R Coll Radiol); 1995; 7(6):366-70. PubMed ID: 8590697
[TBL] [Abstract][Full Text] [Related]
19. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors.
Pichert G; Peters J; Stahel RA; Dommann C; Joss R; Gebbers JO; Kroner T; Sulser H; Honegger HP; Maurer R
Ann Oncol; 1992 Sep; 3(8):645-9. PubMed ID: 1280460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
